Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Tumor-reactive clonotype dynamics dictate clinical response to TIL therapy in melanoma

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Homo sapiens

PROVIDER: GSE229861 | GEO | 2023/08/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Tumor-reactive clonotype dynamics dictate clinical response to TIL therapy in melanoma [TCR-Seq]

Project description:Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TILs) is effective in cancer patients, yet the profiles, specificity and dynamics of tumor clonotypes remain opaque. Using single-cell RNA/TCR-sequencing, clonotypes were tracked from baseline tumors to ACT products (ACTP) and post-ACT blood and tumor samples from 13 metastatic melanoma patients (NCT03475134). Furthermore, a predictor of tumor-reactive clonotypes was derived from the transcriptomic profiles of tumor-specific or bystander clones. Patients with clinical responses had tumors enriched in tumor-reactive TILs, preferentially expanding in-vitro to generate larger and more tumoricidal products and preferentially re-infiltrating tumors post-ACT. Conversely, lack of responses was associated with tumors devoid of tumor-reactive clonotypes and with cell products mostly composed of blood-borne clonotypes. The exhaustion state characterizing intratumoral tumor-reactive TILs was attenuated during in-vitro expansion and restored after tumor re-engraftment only in responders. Thus, tumor-reactive clonotypes drive clinical response to TIL therapy, providing insight to select patients or improve TILs’ culture.

2023-08-01 | GSE234352 | GEO

Tumor-reactive clonotype dynamics dictate clinical response to TIL therapy in melanoma [scTCR-seq]

Project description:Although adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TILs) is effective in cancer patients, immune correlates of efficacy remain opaque. The profiles, specificity and dynamics of tumor clonotypes expanding in vitro, constituting infusion products and then infiltrating tumors after ACT are poorly understood. We observed that tumor-reactive clonotypes drive clinical response to TIL therapy and provide useful insight to improve patients’ selection or TILs’ expansion methodology.

2023-08-01 | GSE229860 | GEO

Tumor-reactive clonotype dynamics dictate clinical response to TIL therapy in melanoma [scRNA-seq]

2023-08-01 | GSE229858 | GEO